Parasternal Nerve Block in Cardiac Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Coronary Artery DiseasePain, Postoperative
Interventions
DRUG

Exparel

"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.~Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."

DRUG

Placebo

"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.~Post-surgical pain management will be the same as for the Exparel group."

Trial Locations (1)

14642

University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

Peter A Knight

OTHER

NCT01826851 - Parasternal Nerve Block in Cardiac Patients | Biotech Hunter | Biotech Hunter